NEW YORK (GenomeWeb) – Veracyte said today that Highmark and Horizon Blue Cross Blue Shield of New Jersey issued positive coverage policies for the company's Afirma Gene Expression Classifier.

Both insurers are affiliated with Blue Cross Blue Shield and have classified Veracyte's genomic test as medically necessary for use in evaluating thyroid nodule fine needle aspiration biopsies that are indeterminate following traditional cytopathology review. The Afirma GEC test helps physicians determine which patients may need surgery as part of a thyroid cancer diagnosis.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: the Human Silencing Hub protein complex, and more.

Heads of various research funding agencies discuss how to encourage scientific breakthroughs, ScienceInsider reports.

The Kansas City Star examines issues surrounding newborn genome sequencing.

Researchers say their Research Resource Identifier citation format is catching on, Nature News reports.